1. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized placebocontrolled clinical trial. Ann Intern Med 1991; 114(10): 835-9.
2. Lewis HD, Dawis JW, Archibald DG, et al. protective effects of aspirin against acute myocardial infarction and deatg in men with unstable angina. Results of a Veterans administration Cooperative Study. N Engl J Med 1983; 309(7): 396-403.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-60.
4. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316-20.
5. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338(8779): 1345-9.
6. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. 3-e izdanie. Moskva 2005; 1527 s.
7. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.
8. Rojas-Fernandez CH, Kephart GC, Sketris IC, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the population-based Nova Scotia Health Survey. Can J Cardiol 1999; 15(3): 291-6.
9. American Stroke Association/American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 2005:1-60.
10. Antitrombotic Trialist’s Collaboration. Collaborative metaanalysis of randomized trials of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
11. Becker RC, Meade TW, Berger PB, et al. American College of chest physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8-th Edition). Chest 2008; 133(6 Suppl): 776S-814.
12. Graham I, Atar D, Borch-Johnsen K, et al. European Society of Cardiology (ESC); European Society for Cardiovascular Prevention and Rehabilitation (EACRR); Council on Cardiovascular Nursing; et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 1): E1-40.
13. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 373(9678): 1849-60.
14. Burwen DR, Galusha DH, Lewis JM, et al. National and State trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163(12): 1430-9.
15. Zaninelli A, Kaufholz C, Scwappach D. Physicians attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgraduate Medicine 2009; 2(6): 44-53.
16. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124(3): 292-8.
17. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147(2): 293-300.
18. Garcia Rodriguez LA, Patrignani P, Gonzalez-Perez A. Risk of myocardial infarction persisting after discontinuation of nonsteroidal anti-inflammatory drugs in the general population. J Thromb Haemost 2009; 7: 892-4.
19. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task Force on ACEinhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.
20. Rafal'skii V.V., Krikova A.V., Baglikov A.N. Osobennosti klinicheskoi farmakologii atsetilsalitsilovoi kisloty kak antitromboticheskogo preparata. Kardiovask ter profil 2009; 8(7): 1-6.
21. Averkov O.V. Atsetilsalitsilovaya kislota kak lekarstvennoe sredstvo: kakie lekarstvennye formy preparata predpochtitel'nee s pozitsii dokazatel'noi meditsiny? Kardiovask ter profil 2010; 2: 61-8.
22. Vasyuk Yu.A., Shal'nova S.A., Shkol'nik E.L., Kulikov K.G. Issledovanie PRIMA: trimetazidin s modifitsirovannym vysvobozhdeniem deistvuyushchego veshchestva v lechenii patsientov so stabil'noi stenokardiei, perenesshikh infarkt miokarda. Epidemiologicheskii i klinicheskii etapy. Kardiologiya 2008; 12: 10-3.
23. Oganisyan N.S., Dmitrieva N.A., Kochetkov A.M., Martsevich S.Yu. Osobennosti diagnostiki i vtorichnoi profilaktiki arterial'noi gipertonii po rezul'tatam oprosa vrachei. RFK 2006; 2: 37-42.